Impact of HBV serological status on HIV virological efficacy of two‐drug antiretroviral regimens: A retrospective observational study on virologically suppressed people with HIV switching to lamivudine/dolutegravir

Documents similaires

• Effectiveness and tolerability of dolutegravir/lamivudine in virologically suppressed people with HIV at 96 weeks in a multicentre cohort
  par: Inés Suárez‐García, et autres
  Publié: (2025)
• Real‐world effectiveness and safety of switching to dolutegravir/lamivudine among people living with HIV‐1 aged over 50 years who are virologically suppressed
  par: C. Piñeiro, et autres
  Publié: (2024)
• Efficacy and safety of dolutegravir/lamivudine in virologically suppressed female participants: week 48 data from the pooled TANGO and SALSA studies
  par: C. Katlama, et autres
  Publié: (2024)
• Clinical management of detectable viraemia during CAB / RPV long‐acting therapy: Are really PIs the only exit strategies?
  par: P. F. Salvo, et autres
  Publié: (2026)
• Association between markers of hepatitis B virus infection and risk of virological rebound in people with HIV receiving antiretroviral therapy
  par: Vincenzo Malagnino, et autres
  Publié: (2024)